Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Certified Advisory Corp

Certified Advisory Corp decreased its position in Gilead Sciences, Inc. (NASDAQ:GILDFree Report) by 2.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,382 shares of the biopharmaceutical company’s stock after selling 230 shares during the quarter. Certified Advisory Corp’s holdings in Gilead Sciences were worth $922,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Tompkins Financial Corp boosted its stake in Gilead Sciences by 223.1% in the third quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 241 shares during the period. Fortitude Family Office LLC acquired a new position in Gilead Sciences in the 4th quarter worth approximately $29,000. Private Wealth Management Group LLC purchased a new position in shares of Gilead Sciences during the fourth quarter valued at $29,000. Sachetta LLC purchased a new position in Gilead Sciences during the fourth quarter valued at approximately $30,000. Finally, Rakuten Securities Inc. purchased a new position in Gilead Sciences in the fourth quarter valued at about $33,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analysts Set New Price Targets

GILD has been the subject of several recent analyst reports. Truist Financial lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating and lowered their target price for the company from $91.00 to $82.00 in a research note on Thursday, February 22nd. Barclays dropped their price target on shares of Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating for the company in a research report on Monday, April 29th. Oppenheimer reiterated an “outperform” rating and set a $105.00 target price on shares of Gilead Sciences in a research report on Friday, April 19th. TD Cowen decreased their target price on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a report on Friday, April 26th. Finally, Cantor Fitzgerald dropped their price objective on shares of Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating for the company in a research report on Wednesday, February 7th. Eleven analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from, the company has an average rating of “Hold” and an average price target of $83.69.

Get Our Latest Stock Report on GILD

Gilead Sciences Stock Up 0.7 %

Shares of NASDAQ:GILD traded up $0.44 during trading on Wednesday, hitting $67.73. 1,311,163 shares of the company were exchanged, compared to its average volume of 7,218,764. The stock has a market cap of $84.38 billion, a price-to-earnings ratio of 186.92, a P/E/G ratio of 1.37 and a beta of 0.22. The company has a current ratio of 1.08, a quick ratio of 0.94 and a debt-to-equity ratio of 1.31. Gilead Sciences, Inc. has a fifty-two week low of $64.33 and a fifty-two week high of $87.86. The firm has a fifty day moving average price of $68.93 and a two-hundred day moving average price of $74.75.

Gilead Sciences (NASDAQ:GILDGet Free Report) last posted its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.49) by $0.17. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The firm had revenue of $6.69 billion for the quarter, compared to analyst estimates of $6.36 billion. During the same period in the prior year, the firm posted $1.37 earnings per share. The company’s quarterly revenue was up 5.3% compared to the same quarter last year. As a group, research analysts anticipate that Gilead Sciences, Inc. will post 3.74 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 27th. Stockholders of record on Friday, June 14th will be paid a dividend of $0.77 per share. The ex-dividend date is Friday, June 14th. This represents a $3.08 annualized dividend and a dividend yield of 4.55%. Gilead Sciences’s dividend payout ratio is currently 855.56%.

Insiders Place Their Bets

In related news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the transaction, the insider now directly owns 96,304 shares of the company’s stock, valued at $7,026,339.84. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 0.29% of the company’s stock.

Gilead Sciences Company Profile

(Free Report)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Further Reading

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with's FREE daily email newsletter.